ストックスクリーナーアプリを入手
3.87
1.31%
0.05
プレマーケット:
3.88
0.010
+0.26%
前日終値:
$3.82
開ける：
$3.84
24時間の取引高:
1.20M
Relative Volume:
0.66
時価総額：
$419.30M
収益：
$27.08M
当期純損益:
$-37.00M
株価収益率:
-7.4423
EPS:
-0.52
ネットキャッシュフロー:
$-18.46M
1週間 パフォーマンス:
-12.64%
1か月 パフォーマンス:
+27.72%
6か月 パフォーマンス:
+127.65%
1年 パフォーマンス:
+57.96%
1日の値動き範囲:
$3.7801
$3.9899
1週間の範囲:
$3.705
$4.84
52週間の値動き範囲:
$1.05
$4.89
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
ACRS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
3.87 | 413.88M | 27.08M | -37.00M | -18.46M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-10 | 再開されました | Piper Sandler | Overweight |
| 2025-05-28 | 開始されました | Wedbush | Outperform |
| 2025-03-18 | 再開されました | Cantor Fitzgerald | Overweight |
| 2024-12-23 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | アップグレード | BTIG Research | Neutral → Buy |
| 2024-11-19 | アップグレード | Jefferies | Hold → Buy |
| 2024-11-19 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | 開始されました | Evercore ISI | Outperform |
| 2022-12-14 | 開始されました | Stifel | Buy |
| 2022-12-01 | 開始されました | Goldman | Buy |
| 2022-10-06 | 開始されました | BTIG Research | Buy |
| 2021-07-23 | 再開されました | Jefferies | Buy |
| 2021-06-15 | 開始されました | Piper Sandler | Overweight |
| 2021-04-21 | 開始されました | H.C. Wainwright | Buy |
| 2019-10-22 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | 開始されました | SVB Leerink | Outperform |
| 2018-03-28 | 再開されました | Leerink Partners | Outperform |
| 2018-02-09 | 開始されました | Guggenheim | Buy |
| 2017-06-16 | 開始されました | Cantor Fitzgerald | Overweight |
| 2016-11-29 | 開始されました | Leerink Partners | Outperform |
| 2016-09-30 | 開始されました | JMP Securities | Mkt Outperform |
| 2016-06-10 | 開始されました | Guggenheim | Buy |
| 2015-11-02 | 開始されました | Citigroup | Buy |
| 2015-11-02 | 開始されました | Jefferies | Buy |
すべてを表示
Aclaris Therapeutics Inc (ACRS) 最新ニュース
Aclaris reports positive preclinical results for hair loss drug By Investing.com - Investing.com Canada
Aclaris Hair Loss Drug Shows Faster Results Than Pfizer's Drug - Benzinga
Aclaris reports positive preclinical results for hair loss drug - Investing.com
Aclaris Therapeutics' ATI-2138 Shows Superior Efficacy Against Ritlecitinib in Alopecia Universalis Model - Quiver Quantitative
Aclaris oral compound restores 93% hair in severe alopecia mice - Stock Titan
Investor Alert: Common Warts Market Set for Rapid Growth – DelveInsight | Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics - Barchart.com
Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) high institutional ownership speaks for itself as stock continues to impress, up 72% over last week - simplywall.st
Market Rankings: What is Aclaris Therapeutics Incs book value per shareProfit Target & High Return Trade Opportunity Guides - baoquankhu1.vn
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Aclaris Therapeutics (NASDAQ:ACRS) nasdaq top 100 Clinical Pipeline - Kalkine Media
Aclaris pushes new antibody into skin disease trial, eyes asthma next - MSN
Aclaris Therapeutics Launches Phase 2 Trial for Promising Atopic Dermatitis Treatment - MSN
Aclaris Therapeutics (NASDAQ:ACRS) Receives Buy Rating from HC Wainwright - MarketBeat
ACRS: Analyst Maintains Buy Rating and $16 Price Target | ACRS S - GuruFocus
There's Reason For Concern Over Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Massive 41% Price Jump - 富途牛牛
Income Plays: What are the future prospects of Aclaris Therapeutics IncWeekly Profit Analysis & Real-Time Stock Entry Alerts - baoquankhu1.vn
Aclaris Therapeutics (NASDAQ:ACRS) Reaches New 1-Year HighHere's What Happened - MarketBeat
Aclaris Pushes New Antibody Into Skin Disease Trial, Eyes Asthma Next - mychesco.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Can Aclaris Therapeutics Inc. (8AT) stock withstand sector downturnsMarket Activity Report & High Accuracy Investment Entry Signals - bollywoodhelpline.com
Aclaris Therapeutics initiates Phase 1b proof-of-concept trial of ATI-052 - Yahoo Finance
Aclaris begins phase 1b trial of ATI-052 for atopic dermatitis - Investing.com Nigeria
Aclaris begins phase 1b trial of ATI-052 for atopic dermatitis By Investing.com - Investing.com South Africa
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052 - The Manila Times
Aclaris Therapeutics, Inc Updates Corporate Overview Presentation - TradingView
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept - GlobeNewswire
Palvella’s QTORIN Pipeline Targets a Breakout Moment in Rare Skin Care - MyChesCo
Why Aclaris Therapeutics Inc. stock could rally in 2025Entry Point & Precise Trade Entry Recommendations - Улправда
Financial Comparison: Aclaris Therapeutics (NASDAQ:ACRS) and Jaguar Animal Health (NASDAQ:JAGX) - Defense World
Will Aclaris Therapeutics Inc. stock benefit from green energy trendsJuly 2025 Earnings & Daily Profit Focused Screening - Улправда
Early trial data puts Aclaris’ ATI-052 on fast track toward bigger bets - MSN
What valuation multiples suggest for Aclaris Therapeutics Inc. stockWeekly Stock Analysis & Long-Term Growth Plans - Улправда
Is Aclaris Therapeutics Inc. stock affected by interest rate hikesTrade Exit Report & Precise Swing Trade Alerts - Улправда
How Aclaris Therapeutics Inc. stock benefits from strong dollar2025 Breakouts & Breakdowns & AI Powered Trade Plan Recommendations - ulpravda.ru
Market Recap: Can Aclaris Therapeutics Inc. (8AT) stock withstand sector downturnsJuly 2025 Pullbacks & Intraday High Probability Alerts - Улправда
Is Aclaris Therapeutics Inc. stock attractive for passive investorsBond Market & Free AI Powered Buy and Sell Recommendations - ulpravda.ru
Why analysts upgrade Aclaris Therapeutics Inc. stockMarket Sentiment Summary & Reliable Momentum Entry Alerts - Улправда
Aclaris joins Nasdaq biotech index, marking milestone for clinical-stage firm - MSN
Early Trial Data Puts Aclaris’ ATI-052 on Fast Track Toward Bigger Bets - mychesco.com
The week in pharma: action, reaction and insight – week to January 19, 2024 - The Pharma Letter
Aclaris Therapeutics Reports Positive Interim Phase 1a ATI-052 Data, Speeds Up Development Plans - Defense World
Jefferies reiterates Buy rating on Aclaris Therapeutics stock at $7 price target By Investing.com - Investing.com South Africa
Jefferies reiterates Buy rating on Aclaris Therapeutics stock at $7 price target - Investing.com Nigeria
Aclaris Therapeutics Reports Positive Phase 1a Data For ATI-052 - Nasdaq
Aclaris advances ATI-052 after positive Phase 1a results - TipRanks
Aclaris reports positive results for anti-inflammatory drug ATI-052 By Investing.com - Investing.com South Africa
Aclaris Therapeutics Announces Positive Interim Results from Phase 1a Trial of ATI-052 - TradingView — Track All Markets
ACRS: ATI-052 showed best-in-class potential in phase 1a, enabling rapid advancement to phase 1b trials - TradingView — Track All Markets
Aclaris Therapeutics Reports Positive Interim Results for ATI-052 Phase 1a Trials and Outlines Future Development Plans - Quiver Quantitative
Aclaris Therapeutics Inc (ACRS) 財務データ
収益
当期純利益
現金流量
EPS
2.09%
0.48%
大文字化:
|
ボリューム (24 時間):